Jon Napitupulu

Humacyte reported third-quarter 2025 revenue of $753,000, primarily driven by a ramp in U.S. sales of SymVESS, its FDA-approved...

Metagenomi has restructured around a single, near-term bet: in vivo genome editing for hemophilia A. The company reported new...

CRISPR Therapeutics reported a mixed but mobilizing third quarter: the first CRISPR-based therapy continues to scale globally. At the...

Novartis has opened a 10,000-square-foot radioligand therapy manufacturing facility in Carlsbad, California, its third U.S. site dedicated to the...

Voyager Therapeutics used its third-quarter update to reset its narrative around neurodegeneration and blood–brain barrier access. The company advanced...

Cabaletta Bio moved its CD19-directed CAR-T program, rese-cel, a step closer to registration, outlining plans to initiate a 14-patient,...

Wave Life Sciences reported third-quarter 2025 results, alongside two meaningful clinical updates that reposition its RNA toolkit squarely in...

4D Molecular Therapeutics has signed an exclusive partnership with Otsuka to develop and commercialize its intravitreal gene therapy 4D-150...

PDS Biotechnology has raised approximately $5.3 million in a registered direct offering, selling 5.8 million shares at $0.91 with...

Recordati reported a strong nine-month performance for 2025, with consolidated revenue up 12.2% to €1.96 billion, EBITDA up 11.8%...